[{"address1": "21 Erie Street", "city": "Cambridge", "state": "MA", "zip": "02139", "country": "United States", "phone": "617 564 0013", "website": "https://primemedicine.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.", "fullTimeEmployees": 234, "companyOfficers": [{"maxAge": 1, "name": "Dr. Keith Michael Gottesdiener M.D., Ph.D.", "age": 69, "title": "President, CEO, Secretary & Director", "yearBorn": 1954, "fiscalYear": 2023, "totalPay": 1059212, "exercisedValue": 0, "unexercisedValue": 678214}, {"maxAge": 1, "name": "Dr. Ann L. Lee Ph.D.", "age": 61, "title": "Chief Technical Officer", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 684782, "exercisedValue": 0, "unexercisedValue": 1773786}, {"maxAge": 1, "name": "Dr. Jeremy S. Duffield M.D., Ph.D.", "age": 55, "title": "Chief Scientific Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 680650, "exercisedValue": 0, "unexercisedValue": 45210}, {"maxAge": 1, "name": "Dr. Andrew  Anzalone M.D., Ph.D.", "age": 36, "title": "Co-Founder & Head of Prime Editing Platform", "yearBorn": 1987, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David R. Liu Ph.D.", "title": "Co-Founder & Chair of Scientific Advisory Board", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Allan  Reine M.D.", "age": 48, "title": "Chief Financial Officer", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Meredith  Goldwasser", "age": 52, "title": "Senior VP and Head of Strategy & Corporate Operations", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Carman  Alenson CPA, M.B.A.", "age": 57, "title": "Senior VP of Finance & Chief Accounting Officer", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Karen  Brown J.D., Ph.D.", "title": "Senior Vice President of Intellectual Property & Legal Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Niamh  Alix", "title": "Chief Human Resources Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 10, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 3.855, "open": 3.85, "dayLow": 3.715, "dayHigh": 3.92, "regularMarketPreviousClose": 3.855, "regularMarketOpen": 3.85, "regularMarketDayLow": 3.715, "regularMarketDayHigh": 3.92, "forwardPE": -2.3584905, "volume": 491671, "regularMarketVolume": 491671, "averageVolume": 761929, "averageVolume10days": 440610, "averageDailyVolume10Day": 440610, "bid": 3.72, "ask": 3.77, "bidSize": 100, "askSize": 400, "marketCap": 450116256, "fiftyTwoWeekLow": 3.715, "fiftyTwoWeekHigh": 13.273, "priceToSalesTrailing12Months": 761.61804, "fiftyDayAverage": 4.9963, "twoHundredDayAverage": 6.5837, "currency": "USD", "enterpriseValue": 327055104, "floatShares": 54177628, "sharesOutstanding": 120031000, "sharesShort": 15894539, "sharesShortPriorMonth": 13716264, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.13239999, "heldPercentInsiders": 0.2627, "heldPercentInstitutions": 0.68057, "shortRatio": 23.36, "shortPercentOfFloat": 0.2782, "bookValue": 1.69, "priceToBook": 2.2189348, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -217439008, "trailingEps": -2.17, "forwardEps": -1.59, "enterpriseToRevenue": 553.393, "enterpriseToEbitda": -1.598, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "PRME", "underlyingSymbol": "PRME", "shortName": "Prime Medicine, Inc.", "longName": "Prime Medicine, Inc.", "firstTradeDateEpochUtc": 1666272600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "b996ad98-2192-38d9-b591-51836033bbfe", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.75, "targetHighPrice": 20.0, "targetLowPrice": 8.0, "targetMeanPrice": 14.0, "targetMedianPrice": 13.5, "recommendationMean": 1.8, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 162868000, "totalCashPerShare": 1.4, "ebitda": -204679008, "totalDebt": 41583000, "quickRatio": 7.849, "currentRatio": 8.232, "totalRevenue": 591000, "debtToEquity": 21.152, "revenuePerShare": 0.006, "returnOnAssets": -0.48563, "returnOnEquity": -0.99584997, "freeCashflow": -110086000, "operatingCashflow": -196228000, "operatingMargins": -355.35532, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]